Original Article

You have full text access to this OnlineOpen article

The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate

  1. Edward T Middleton*,
  2. Susan A Steel,
  3. Mo Aye,
  4. Sheelagh M Doherty

Article first published online: 18 MAR 2010

DOI: 10.1359/jbmr.090821

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 455–462, March 2010

Additional Information

How to Cite

Middleton, E. T., Steel, S. A., Aye, M. and Doherty, S. M. (2010), The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res, 25: 455–462. doi: 10.1359/jbmr.090821

Author Information

  1. Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, United Kingdom

*Centre for Metabolic Bone Disease, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull, UK, HU3 2RW.

Publication History

  1. Issue published online: 18 MAR 2010
  2. Article first published online: 18 MAR 2010
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 27 AUG 2009
  5. Manuscript Revised: 12 AUG 2009
  6. Manuscript Received: 23 JUN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (204K)

References

  • 1
    Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350: 459–468.
  • 2
    Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816–2822.
  • 3
    Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001; 69: 121–129.
  • 4
    Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008; 23: 215–222.
    Direct Link:
  • 5
    Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004; 19: 2012–2020.
    Direct Link:
  • 6
    National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2008 Available at: www.nice.org.uk/nicemedia/pdf/TA161quickrefguide.pdf. Accessed May 1, 2009.
  • 7
    Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX)—a randomized trial. JAMA. 2006; 296: 2927–2938.
  • 8
    Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350: 1189–1199.
  • 9
    Boivin G, Farlay D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralisation of bone after 2 and 3 years of treatment with strontium ranelate in postmenopausal women. Calcif Tissue Int. 2006; 78: S36.
  • 10
    Boivin G, Khebbab MT, Jaurand X, Farlay D, Meunier PJ, Delmas PD. Localization of strontium, by X-ray microanalysis cartography, in bone biopsies of postmenopausal osteoporotic women treated for 3 years with strontium ranelate. Calcif Tissue Int. 2007; 80: S118.
  • 11
    Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 1591–1600.
    Direct Link:
  • 12
    Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19: 745–751.
    Direct Link:
  • 13
    Blake GM, Preston N, Patel R, Herd RJ, Fogelman I. Monitoring skeletal response to treatment which site to measure in the femur? J Clin Densitom. 2000; 3: 149–155.
  • 14
    Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int. 2003; 14: S56–65.
  • 15
    Blake GM, Lewiecki EM, Kendler DL, Fogelman I. A review of strontium ranelate and its effect on DXA scans. J Clin Densitom. 2007; 10: 113–119.
  • 16
    Noble BS, Reeve J. Osteocyte function, osteocyte death and bone fracture resistance. Mol Cell Endocrinol. 2000; 159: 7–13.
  • 17
    Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res. 1996; 11: 1302–1311.
    Direct Link:
  • 18
    Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM. Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 tesla. J Magn Reson Imaging. 2007; 26: 787–793.
    Direct Link:
  • 19
    Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2: 35–43.
  • 20
    Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 2000; 11: S66–76.
  • 21
    Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006; 21: 1113–1120.
    Direct Link:
  • 22
    Seibel MJ. Biochemical markers of bone turnover: I. Biochemistry and variability. Clin Biochem Rev. 2005; 26: 97–122.
  • 23
    Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19: 365–372.
  • 24
    Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20: 962–970.
    Direct Link:
  • 25
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
  • 26
    Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008; 42: 129–138.
  • 27
    Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone. 2001; 29: 176–179.
  • 28
    Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone. 1996; 18: 517–523.
  • 29
    Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008; 93: 852–860.
View Full Article (HTML) Get PDF (204K)